Loading
Patritumab deruxtecan / Nab-paclitaxel / Breast Neoplasms · Phase 3 Trial
ClinicalTrials.gov · August 7, 2026
Early or partial results. Treat as a signal, not a conclusion.
This is a Phase 3 trial registration for patritumab deruxtecan in HR+/HER2− breast cancer that is currently recruiting. No outcome data are available in this registry record; the study is designed to compare progression-free survival and overall survival against chemotherapy and trastuzumab deruxtecan comparators over 45 and 85 months respectively.
Phase 3, Interventional, Randomized, Parallel, Open label, Treatment purpose. Breast Neoplasms; age from 18 Years. Intervention: Patritumab Deruxtecan. Compared with: Treatment of Physician's Choice — Active Comparator. n = 1,000. 197 sites across 26 countries.
This is a Phase 3 trial registration for patritumab deruxtecan in HR+/HER2− breast cancer that is currently recruiting. No outcome data are available in this registry record; the study is designed to compare progression-free survival and overall survival against chemotherapy and trastuzumab deruxtecan comparators over 45 and 85 months respectively.
No interim or preliminary efficacy or safety data are available.
The source did not state who this applies to in practice.
This is an active Phase 3 trial registration with no results reported; it describes a planned comparison but cannot yet support clinical evidence or practice guidance.
As stated by the source record.
Quoted from the source exactly as published.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
What is missing. This record has no key findings. That is a gap in the analysis, not a judgement about the study.
Registry record from ClinicalTrials.gov (NCT07060807). This is a study registration, not published results. Lead sponsor: Merck Sharp & Dohme LLC. Recruitment status: RECRUITING. Phase: PHASE3. Study type: INTERVENTIONAL. Enrollment: 1000 participants (ESTIMATED). Conditions: Breast Neoplasms. Interventions: BIOLOGICAL: Patritumab deruxtecan; DRUG: Paclitaxel; DRUG: Nab-paclitaxel; DRUG: Capecitabine; DRUG: Liposomal doxorubicin; BIOLOGICAL: Trastuzumab deruxtecan. Primary outcome measures: Progression Free Survival (PFS) , Up to approximately 45 months; Overall Survival (OS) , Up to approximately 85 months. Brief summary: Researchers are looking for other ways to treat breast cancer (BC) that is hormone receptor-positive and human epidermal growth factor receptor 2-negative (HR+/HER2-) and either unresectable locally advanced or metastatic. * HR positive (HR+) means the cancer cells have proteins that attach to estrogen or progesterone (hormones) which help the cancer to grow and spread * HER2 negative (HER2-) means the cancer cells have a low amount of a protein called HER2 * Unresectable locally advanced means the cancer cannot be completely removed by surgery and has spread into nearby tissue or muscles * Metastatic means the cancer has spread to other parts of the body Treatment for this type of breast cancer usually includes endocrine therapy (ET) and sometimes a second treatment. The main goal of this study is to learn if people who receive patritumab deruxtecan (also known as HER3-DXd and MK-1022) live longer overall or without the cancer growing/spreading, compared to people who receive chemotherapy or a different drug called trastuzumab deruxtecan.
Taken from the source record, never inferred. Follow any of these and new work involving them reaches your briefing.